Jeffrey Wager is the founder of Spexis. Spexis has raised $8M in total funding. Latest round: Growth. Backed by CARB-X, SPRIM Global Investments.
Jeffrey Wager is the Chairman & CEO of Spexis AG, a clinical-stage biopharmaceutical company based in Allschwil, Switzerland. The company focuses on macrocycle therapeutics for rare diseases and oncology. Spexis recently secured USD $7.5 million in capital commitments to support its Phase 3 ColiFin® program for cystic fibrosis infections.
Full founder directory · Investor directory · Company funding database · Fundraising library